BridgeBio Pharma Total Liabilities

BridgeBio Pharma posts a total liabilities of $3.6B as of March 2026. That compares with $2.5B in the prior-year period — up 44.4% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, BridgeBio Pharma's total liabilities was $2.5B. The latest reading is $3.6B — a 44.4% year-over-year increase (period ending March 2026). Use the history and growth charts on this page for a longer lookback.

Total Liabilities is one piece of BridgeBio Pharma's financial statement story. At $3.6B, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for BBIO's total liabilities usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; BridgeBio Pharma's other metric pages and overview cover the third.

Judging BridgeBio Pharma against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in total liabilities easier to interpret. Start with $3.6B here, then scan peer and history charts to see if the gap is persistent.